1 Onkologisk Klinik, Finsencentret, Rigshospitalet, The Capital Region of Denmark2 CHU Jean Minjoz, Besançon, France. email@example.com unknown
an open-label randomised study
Subcutaneous trastuzumab has shown non-inferior efficacy and a similar pharmacokinetic and safety profile when compared with intravenous trastuzumab in patients with HER2-positive early breast cancer. We assessed patient preference for either subcutaneous or intravenous trastuzumab in the international, randomised PrefHer study.
Lancet Oncology, 2013, Vol 14, Issue 10, p. 962-70